Blog

At the 35th International Symposium on ALS/MND, held from December 6-8, 2024, at the Montreal Convention Center, AcuraStem Chief Scientific Officer Marcel van der Brug delivered a key presentation titled 'Development of an UNC13A Cryptic Exon Skipping Antisense Oligonucleotide as a Treatment for ALS.

AcuraStem announced the appointment of Marcel van der Brug, Ph.D., as Chief Scientific Officer. Dr. van der Brug is an accomplished neuroscientist with extensive expertise in neurodegenerative diseases and therapeutic development.

At the RNA Leaders USA Congress, held September 4-5, 2024, at the San Diego Convention Center, AcuraStem CEO Sam Alworth delivered a key presentation titled 'Accelerating the Development of More Effective Treatments for ALS & FTD Using the iNeuroRx® Technology Platform.'

AcuraStem, a patient-based biotechnology company advancing treatments for amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases, announced today that it has successfully secured $4 million in grant funding from the California Institute for Regenerative Medicine (CIRM) as part of CIRM's Therapeutic Translational Research Projects program, which accelerates the preclinical development of innovative therapies.

AcuraStem, a patient-based biotechnology company pioneering the development of treatments for neurodegenerative diseases, today announced the appointment of Dr. Rafael Renteria as Principal Scientist, hiPSC Platform.

AcuraStem, a patient-based biotechnology company advancing treatments for amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases, announced today that CEO Sam Alworth has been invited to speak at the RNA Leaders USA Congress, scheduled for September 4-5, 2024, at the San Diego Convention Center.

AcuraStem, a patient-based biotechnology company pioneering the development of treatments for neurodegenerative diseases, today announced the appointment of Dr. Ananya Sengupta as Associate Director of Program Management

AcuraStem’s Associate Vice President, Discovery and Early Development, Dr. Wen-Hsuan (Wen) Chang, will present at the 5th International Oligonucleotides and Peptides Conference (IOPC) on June 26, 2024, in Milan

AcuraStem, a patient-based biotechnology company pioneering the development of treatments for neurodegenerative diseases, today announced it has named Dr. Wen-Hsuan Chang as Associate Vice President of Discovery and Early Development

AcuraStem proudly sponsored the recent IgNight ALS event in Washington, D.C., a poignant evening dedicated to celebrating Steve Gleason and his profound contributions to the ALS community